International Stem Cell (ISCO) Net Margin (2010 - 2026)

International Stem Cell (ISCO) has reported Net Margin for 17 consecutive years, with 2.65% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin fell 539.0% year-over-year to 2.65% in Q2 2026; TTM through Jun 2026 was 3.35%, a 7.0% decrease from a year earlier, with the FY2025 full-year figure at 4.59%, down 225.0% from the prior year.
• Net Margin was 2.65% for Q2 2026 at International Stem Cell, up from 16.15% in the prior quarter.
• Over five years, Net Margin peaked at 14.07% in Q2 2023 and troughed at 24.25% in Q4 2023.
• A 5-year average of 4.56% and a median of 1.63% in 2023 frame the typical range for Net Margin.
• Across the five-year window, Net Margin jumped 3568 bps in 2022 and slumped 2540 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 1.15% in 2022, then sank by 2204 bps to 24.25% in 2023, then surged by 102 bps to 0.49% in 2024, then plunged by 3392 bps to 16.15% in 2025, then soared by 84 bps to 2.65% in 2026.
• The last three Net Margin figures came in at 2.65% (Q2 2026), 16.15% (Q4 2025), and 1.22% (Q3 2025), per Business Quant data.